Physician profile
Caitlin Basnight
NPI 1043702954
$1,359.16
in general payments reported to CMS, 2019-2025
23 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $45.81 · 2021: $169 · 2022: $351 · 2023: $342 · 2024: $121 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $604.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $295.70 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $268.72 | 2019-2023 | |
| Insulet Corporation | $118.04 | 2022-2024 | Omnipod |
| Lilly USA, LLC | $107.08 | 2022-2025 | Jardiance, Mounjaro, Emgality |
| Abbvie INC. | $101.74 | 2022-2025 | Ubrelvy, Linzess |
| Abbott Laboratories | $85.08 | 2021-2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $69.95 | 2022-2025 | Airsupra, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.85 | 2023-2024 | Xifaxan |
| Exact Sciences Corporation | $34.72 | 2023-2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $31.12 | 2022 | |
| Amgen INC. | $26.33 | 2020-2022 | |
| Shire North American Group INC | $20.17 | 2019 | |
| Smith+Nephew, INC. | $20.06 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.98 | 2023 | Gvoke Hypopen |
| Shield Therapeutics INC | $16.71 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $16.26 | 2021 | |
| Esperion Therapeutics, INC. | $15.33 | 2021 | |
| Allergan, INC. | $14.43 | 2019 | |
| Merck Sharp & Dohme LLC | $14.01 | 2025 | M-M-R II, Capvaxive, Vaxneuvance |
| Bioventus LLC | $13.47 | 2021 | |
| Pfizer INC. | $11.20 | 2019 | |
| Phathom Pharmaceuticals, INC. | $9.07 | 2025 | Voquezna |
| Organon LLC | $7.14 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Basnight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.